Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products
Identifieur interne : 001C87 ( Istex/Corpus ); précédent : 001C86; suivant : 001C88Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products
Auteurs : J. Li ; D. De Korte ; M. D. Woolum ; P. H. Ruane ; S. D. Keil ; O. Lockerbie ; R. Mclean ; R. P. GoodrichSource :
- Vox Sanguinis [ 0042-9007 ] ; 2004-08.
English descriptors
- Teeft :
- Apheresis, Apheresis platelet, Apheresis products, Appc, Appc products, Bacterial contamination, Bcpc, Blackwell publishing, Blood components, Blood products, Buffy, Buffy coat platelet, Buffy coat platelets, Buffy coat products, Buffy coats, Cell counts, Cell population, Cell quality, Control bcpc, Days treatment, Energy metabolism, Glucose, Goodrich, Hplc, Lactate, Lactate production, Liquid chromatography, Lumichrome, Mass spectrum, Microparticle formation, Mitochondria integrity, Mitochondrion, Navigant biotechnologies, Pathogen, Pco2, Photoproducts, Platelet, Platelet activation, Platelet morphology, Platelet products, Platelet storage, Room temperature, Sanguinis, Standard deviation, Statistical difference, Transfusion, Whole blood, Whole blood units.
Abstract
Background and Objectives A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on in vitro cell quality and on riboflavin conversion in PC. Materials and Methods BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed. Results Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome. Conclusions PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.
Url:
DOI: 10.1111/j.1423-0410.2004.00548.x
Links to Exploration step
ISTEX:933E5413A4419F06FFEB2ECA3F8E362037753B24Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><author><name sortKey="Li, J" sort="Li, J" uniqKey="Li J" first="J." last="Li">J. Li</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="De Korte, D" sort="De Korte, D" uniqKey="De Korte D" first="D." last="De Korte">D. De Korte</name><affiliation><mods:affiliation>Sanquin Research at CLB, Amsterdam, the Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Woolum, M D" sort="Woolum, M D" uniqKey="Woolum M" first="M. D." last="Woolum">M. D. Woolum</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Ruane, P H" sort="Ruane, P H" uniqKey="Ruane P" first="P. H." last="Ruane">P. H. Ruane</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Keil, S D" sort="Keil, S D" uniqKey="Keil S" first="S. D." last="Keil">S. D. Keil</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Lockerbie, O" sort="Lockerbie, O" uniqKey="Lockerbie O" first="O." last="Lockerbie">O. Lockerbie</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Mclean, R" sort="Mclean, R" uniqKey="Mclean R" first="R." last="Mclean">R. Mclean</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Goodrich, R P" sort="Goodrich, R P" uniqKey="Goodrich R" first="R. P." last="Goodrich">R. P. Goodrich</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: ray.goodrich@navigantbiotech.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:933E5413A4419F06FFEB2ECA3F8E362037753B24</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1111/j.1423-0410.2004.00548.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001C87</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001C87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><author><name sortKey="Li, J" sort="Li, J" uniqKey="Li J" first="J." last="Li">J. Li</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="De Korte, D" sort="De Korte, D" uniqKey="De Korte D" first="D." last="De Korte">D. De Korte</name><affiliation><mods:affiliation>Sanquin Research at CLB, Amsterdam, the Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Woolum, M D" sort="Woolum, M D" uniqKey="Woolum M" first="M. D." last="Woolum">M. D. Woolum</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Ruane, P H" sort="Ruane, P H" uniqKey="Ruane P" first="P. H." last="Ruane">P. H. Ruane</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Keil, S D" sort="Keil, S D" uniqKey="Keil S" first="S. D." last="Keil">S. D. Keil</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Lockerbie, O" sort="Lockerbie, O" uniqKey="Lockerbie O" first="O." last="Lockerbie">O. Lockerbie</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Mclean, R" sort="Mclean, R" uniqKey="Mclean R" first="R." last="Mclean">R. Mclean</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation></author><author><name sortKey="Goodrich, R P" sort="Goodrich, R P" uniqKey="Goodrich R" first="R. P." last="Goodrich">R. P. Goodrich</name><affiliation><mods:affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: ray.goodrich@navigantbiotech.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Vox Sanguinis</title><title level="j" type="alt">VOX SANGUINIS</title><idno type="ISSN">0042-9007</idno><idno type="eISSN">1423-0410</idno><imprint><biblScope unit="vol">87</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="82">82</biblScope><biblScope unit="page" to="90">90</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-08">2004-08</date></imprint><idno type="ISSN">0042-9007</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-9007</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Apheresis</term><term>Apheresis platelet</term><term>Apheresis products</term><term>Appc</term><term>Appc products</term><term>Bacterial contamination</term><term>Bcpc</term><term>Blackwell publishing</term><term>Blood components</term><term>Blood products</term><term>Buffy</term><term>Buffy coat platelet</term><term>Buffy coat platelets</term><term>Buffy coat products</term><term>Buffy coats</term><term>Cell counts</term><term>Cell population</term><term>Cell quality</term><term>Control bcpc</term><term>Days treatment</term><term>Energy metabolism</term><term>Glucose</term><term>Goodrich</term><term>Hplc</term><term>Lactate</term><term>Lactate production</term><term>Liquid chromatography</term><term>Lumichrome</term><term>Mass spectrum</term><term>Microparticle formation</term><term>Mitochondria integrity</term><term>Mitochondrion</term><term>Navigant biotechnologies</term><term>Pathogen</term><term>Pco2</term><term>Photoproducts</term><term>Platelet</term><term>Platelet activation</term><term>Platelet morphology</term><term>Platelet products</term><term>Platelet storage</term><term>Room temperature</term><term>Sanguinis</term><term>Standard deviation</term><term>Statistical difference</term><term>Transfusion</term><term>Whole blood</term><term>Whole blood units</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background and Objectives A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on in vitro cell quality and on riboflavin conversion in PC. Materials and Methods BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed. Results Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome. Conclusions PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>platelet</json:string><json:string>bcpc</json:string><json:string>appc</json:string><json:string>transfusion</json:string><json:string>buffy</json:string><json:string>apheresis</json:string><json:string>pathogen</json:string><json:string>glucose</json:string><json:string>mitochondrion</json:string><json:string>appc products</json:string><json:string>lumichrome</json:string><json:string>whole blood</json:string><json:string>photoproducts</json:string><json:string>sanguinis</json:string><json:string>blackwell publishing</json:string><json:string>hplc</json:string><json:string>apheresis platelet</json:string><json:string>cell counts</json:string><json:string>goodrich</json:string><json:string>pco2</json:string><json:string>buffy coat platelets</json:string><json:string>buffy coat platelet</json:string><json:string>cell quality</json:string><json:string>platelet morphology</json:string><json:string>lactate</json:string><json:string>mitochondria integrity</json:string><json:string>room temperature</json:string><json:string>lactate production</json:string><json:string>blood products</json:string><json:string>blood components</json:string><json:string>platelet activation</json:string><json:string>microparticle formation</json:string><json:string>whole blood units</json:string><json:string>days treatment</json:string><json:string>buffy coats</json:string><json:string>control bcpc</json:string><json:string>platelet storage</json:string><json:string>platelet products</json:string><json:string>bacterial contamination</json:string><json:string>standard deviation</json:string><json:string>apheresis products</json:string><json:string>navigant biotechnologies</json:string><json:string>statistical difference</json:string><json:string>liquid chromatography</json:string><json:string>buffy coat products</json:string><json:string>cell population</json:string><json:string>energy metabolism</json:string><json:string>mass spectrum</json:string></teeft></keywords><author><json:item><name>J. Li</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>D. De Korte</name><affiliations><json:string>Sanquin Research at CLB, Amsterdam, the Netherlands</json:string></affiliations></json:item><json:item><name>M. D. Woolum</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>P. H. Ruane</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>S. D. Keil</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>O. Lockerbie</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>R. McLean</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string></affiliations></json:item><json:item><name>R. P. Goodrich</name><affiliations><json:string>Navigant Biotechnologies Inc., Lakewood, CO, USA</json:string><json:string>E-mail: ray.goodrich@navigantbiotech.com</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>apheresis platelet concentrate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>buffy coat platelet concentrate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>pathogen‐reduction technology</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>riboflavin</value></json:item></subject><articleId><json:string>VOX548</json:string></articleId><arkIstex>ark:/67375/WNG-7MMLP8DQ-P</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Background and Objectives A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on in vitro cell quality and on riboflavin conversion in PC. Materials and Methods BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed. Results Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome. Conclusions PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.</abstract><qualityIndicators><score>10</score><pdfWordCount>5765</pdfWordCount><pdfCharCount>34659</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595 x 782 pts</pdfPageSize><pdfWordsPerPage>641</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>305</abstractWordCount><abstractCharCount>2000</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><pmid><json:string>15355498</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Vox Sanguinis</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1423-0410</json:string></doi><issn><json:string>0042-9007</json:string></issn><eissn><json:string>1423-0410</json:string></eissn><publisherId><json:string>VOX</json:string></publisherId><volume>87</volume><issue>2</issue><pages><first>82</first><last>90</last><total>9</total></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2004</json:string></date><geogName></geogName><orgName><json:string>Lakewood, CO</json:string><json:string>Promega Corporation</json:string><json:string>Netherlands, Spain, Germany, UK, France</json:string><json:string>Braun Medical Inc.</json:string><json:string>Navigant Biotechnologies, Inc.</json:string><json:string>Council of Europe:</json:string><json:string>Blackwell Publishing Ltd</json:string><json:string>Navigant Biotechnologies Inc.</json:string><json:string>AABB</json:string><json:string>Council of Europe</json:string><json:string>American Association of Blood Bank</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Alain Segers</json:string><json:string>P. H. Ruane</json:string><json:string>Kristin Bjorgo</json:string><json:string>D. Woolum</json:string><json:string>In</json:string><json:string>Joe Rice</json:string><json:string>The</json:string><json:string>Roland</json:string><json:string>R. P. Goodrich</json:string><json:string>D. de Korte</json:string><json:string>S. D. Keil</json:string></persName><placeName><json:string>Madison</json:string><json:string>Amsterdam</json:string><json:string>CA</json:string><json:string>Copenhagen</json:string><json:string>WI</json:string><json:string>Irvine</json:string><json:string>Mountain View</json:string><json:string>Netherlands</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[23]</json:string><json:string>[29]</json:string><json:string>[6]</json:string><json:string>[2,3]</json:string><json:string>[33]</json:string><json:string>[28]</json:string><json:string>[1]</json:string><json:string>[32]</json:string><json:string>[27]</json:string><json:string>[3]</json:string><json:string>[31]</json:string><json:string>[5]</json:string><json:string>[37]</json:string><json:string>[30]</json:string><json:string>J. Li et al.</json:string><json:string>[36]</json:string><json:string>[2]</json:string><json:string>[35]</json:string><json:string>[38,39]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-7MMLP8DQ-P</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - hematology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - cardiovascular system & hematology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Hematology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - endocrinopathies</json:string></inist></categories><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1111/j.1423-0410.2004.00548.x</json:string></doi><id>933E5413A4419F06FFEB2ECA3F8E362037753B24</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><title level="a" type="short">PRT on BC and AP platelet concentrates</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-08"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><title level="a" type="short">PRT on BC and AP platelet concentrates</title><author xml:id="author-0000"><persName><forename type="first">J.</forename><surname>Li</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">D.</forename><surname>De Korte</surname></persName><affiliation><orgName type="laboratory">Sanquin Research at CLB</orgName><address><addrLine>Amsterdam</addrLine><addrLine>the Netherlands</addrLine><country key="NL" xml:lang="en">THE NETHERLANDS</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">M. D.</forename><surname>Woolum</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">P. H.</forename><surname>Ruane</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">S. D.</forename><surname>Keil</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">O.</forename><surname>Lockerbie</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">R.</forename><surname>McLean</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0007" role="corresp"><persName><forename type="first">R. P.</forename><surname>Goodrich</surname></persName><affiliation><address><addrLine>Navigant Biotechnologies Inc.</addrLine><addrLine>Lakewood, CO, USA</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">933E5413A4419F06FFEB2ECA3F8E362037753B24</idno><idno type="ark">ark:/67375/WNG-7MMLP8DQ-P</idno><idno type="DOI">10.1111/j.1423-0410.2004.00548.x</idno><idno type="unit">VOX548</idno><idno type="toTypesetVersion">file:VOX.VOX548.pdf</idno></analytic><monogr><title level="j" type="main">Vox Sanguinis</title><title level="j" type="alt">VOX SANGUINIS</title><idno type="pISSN">0042-9007</idno><idno type="eISSN">1423-0410</idno><idno type="book-DOI">10.1111/(ISSN)1423-0410</idno><idno type="book-part-DOI">10.1111/vox.2004.87.issue-2</idno><idno type="product">VOX</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">87</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="82">82</biblScope><biblScope unit="page" to="90">90</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2004-08"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><p><hi rend="bold">Background and Objectives </hi> A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on <hi rend="italic">in vitro</hi> cell quality and on riboflavin conversion in PC.</p><p><hi rend="bold">Materials and Methods </hi> BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed.</p><p><hi rend="bold">Results </hi> Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome.</p><p><hi rend="bold">Conclusions </hi> PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.</p></abstract><textClass><keywords xml:lang="en"><term xml:id="k1">apheresis platelet concentrate</term><term xml:id="k2">buffy coat platelet concentrate</term><term xml:id="k3">pathogen‐reduction technology</term><term xml:id="k4">riboflavin</term></keywords><keywords rend="tocHeading1"><term>Transfusion‐Transmitted Disease and its Prevention</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Science Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1423-0410</doi><issn type="print">0042-9007</issn><issn type="electronic">1423-0410</issn><idGroup><id type="product" value="VOX"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="VOX SANGUINIS">Vox Sanguinis</title></titleGroup></publicationMeta><publicationMeta level="part" position="08002"><doi origin="wiley">10.1111/vox.2004.87.issue-2</doi><numberingGroup><numbering type="journalVolume" number="87">87</numbering><numbering type="journalIssue" number="2">2</numbering></numberingGroup><coverDate startDate="2004-08">August 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1423-0410.2004.00548.x</doi><idGroup><id type="unit" value="VOX548"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="tocHeading1">Transfusion‐Transmitted Disease and its Prevention</title></titleGroup><eventGroup><event type="firstOnline" date="2004-09-06"></event><event type="publishedOnlineFinalForm" date="2004-09-06"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-02-27"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="82">82</numbering><numbering type="pageLast" number="90">90</numbering></numberingGroup><correspondenceTo><i>Correspondence</i>: Raymond P. Goodrich, Navigant Biotechnologies, Inc., 1215 Quail Street, Lakewood, Colorado 80215, USA
E‐mail: <email>ray.goodrich@navigantbiotech.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:VOX.VOX548.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received: 19 February 2004, revised 22 June 2004, accepted 26 June 2004</unparsedEditorialHistory><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="39"></count><count type="wordTotal" number="4812"></count></countGroup><titleGroup><title type="main">Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title><title type="shortAuthors">J. Li <i>et al.</i></title><title type="short">PRT on BC and AP platelet concentrates</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>J.</givenNames><familyName>Li</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a2"><personName><givenNames>D.</givenNames><familyName>De Korte</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>M. D.</givenNames><familyName>Woolum</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>P. H.</givenNames><familyName>Ruane</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1"><personName><givenNames>S. D.</givenNames><familyName>Keil</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1"><personName><givenNames>O.</givenNames><familyName>Lockerbie</familyName></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a1"><personName><givenNames>R.</givenNames><familyName>McLean</familyName></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1" corresponding="yes"><personName><givenNames>R. P.</givenNames><familyName>Goodrich</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="NL"><unparsedAffiliation>Sanquin Research at CLB, Amsterdam, the Netherlands</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">apheresis platelet concentrate</keyword><keyword xml:id="k2">buffy coat platelet concentrate</keyword><keyword xml:id="k3">pathogen‐reduction technology</keyword><keyword xml:id="k4">riboflavin</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Background and Objectives </b> A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on <i>in vitro</i> cell quality and on riboflavin conversion in PC.</p><p><b>Materials and Methods </b> BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed.</p><p><b>Results </b> Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome.</p><p><b>Conclusions </b> PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PRT on BC and AP platelet concentrates</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Li</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D.</namePart><namePart type="family">De Korte</namePart><affiliation>Sanquin Research at CLB, Amsterdam, the Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. D.</namePart><namePart type="family">Woolum</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P. H.</namePart><namePart type="family">Ruane</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. D.</namePart><namePart type="family">Keil</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O.</namePart><namePart type="family">Lockerbie</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">McLean</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R. P.</namePart><namePart type="family">Goodrich</namePart><affiliation>Navigant Biotechnologies Inc., Lakewood, CO, USA</affiliation><affiliation>E-mail: ray.goodrich@navigantbiotech.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Blackwell Science Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2004-08</dateIssued><edition>Received: 19 February 2004, revised 22 June 2004, accepted 26 June 2004</edition><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="formulas">0</extent><extent unit="references">39</extent><extent unit="words">4812</extent></physicalDescription><abstract lang="en">Background and Objectives A pathogen‐reduction technology (PRT) system using riboflavin and light has been developed for the treatment of platelet concentrates (PC) obtained by either buffy coat preparation (BCPC) or apheresis procedures (APPC). The aim of this study was to evaluate the effects of the treatment process on in vitro cell quality and on riboflavin conversion in PC. Materials and Methods BCPC were prepared with the Compomat G4™ from whole blood which had been stored overnight after collection. APPC were obtained using the TRIMA™ apheresis procedure. Both PC products had been stored for 18–24 h prior to PRT treatment. BCPC and APPC were treated with PRT on day 2 and day 1 of shelf‐life, respectively. The treated PCs were then maintained for an additional 5 days after the PRT treatment. A panel of cell quality assays and high‐performance liquid chromatography (HPLC) analysis were performed. Results Cell counts and plasma lactate dehydrogenase (LDH) levels during storage indicated that PRT did not induce significant cell lysis. Acceleration of a decrease in glucose and an increase in lactate was observed for treated PCs, but no significant differences were observed between treated BCPC and APPC. The pH of treated samples remained above 7·0, although was lower than that of the control. Platelet morphology of BCPC and APPC was well preserved. P‐selectin expression indicated significant platelet activation when compared with control PC (BCPC on day 6: 39% vs. 12%; APPC on day 5: 35% vs. 18%). Both P‐selectin expression and microparticle formation were not significantly different between treated BCPC and APPC during storage. The JC‐1 assay also displayed no loss of mitochondria integrity during the storage of treated products. Approximately 20% of riboflavin converted into photoproducts, including lumichrome. Conclusions PRT treatment had an effect on the development of the normal platelet storage lesion at a level which seems tolerable for clinical usage.</abstract><subject lang="en"><genre>keywords</genre><topic>apheresis platelet concentrate</topic><topic>buffy coat platelet concentrate</topic><topic>pathogen‐reduction technology</topic><topic>riboflavin</topic></subject><relatedItem type="host"><titleInfo><title>Vox Sanguinis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0042-9007</identifier><identifier type="eISSN">1423-0410</identifier><identifier type="DOI">10.1111/(ISSN)1423-0410</identifier><identifier type="PublisherID">VOX</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>82</start><end>90</end><total>9</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Improving the bacteriological safety of platelet transfusions</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Blajchman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goldman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F</namePart><namePart type="family">Baeza</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Blajchman MA, Goldman M, Baeza F: Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004; 18: 11–24</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>11</start><end>24</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Rev</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>11</start><end>24</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Current and emerging infectious risks of blood transfusions</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Busch</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Kleinman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GJ</namePart><namePart type="family">Nemo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 2003; 289: 959–62</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>959</start><end>62</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>289</number></detail><extent unit="pages"><start>959</start><end>62</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>Emily Cooley Lecture 2002: transfusion safety in the hospital.:</title></titleInfo><name type="personal"><namePart type="given">WH</namePart><namePart type="family">Dzik</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dzik WH: Emily Cooley Lecture 2002: transfusion safety in the hospital.: Transfusion 2003; 43: 1190–99</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1190</start><end>99</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>1190</start><end>99</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>Single‐donor platelets reduce the risk of septic platelet transfusion reactions</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Ness</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Braine</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">King</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Barraso</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Kickler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Fuller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Blades</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ness P, Braine H, King K, Barraso C, Kickler T, Fuller A, Blades N: Single‐donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41: 857–61</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>857</start><end>61</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>857</start><end>61</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Yomtovian</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HM</namePart><namePart type="family">Lazarus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LT</namePart><namePart type="family">Goodnough</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NV</namePart><namePart type="family">Hirschler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Morrissey</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Jacobs</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR: A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 1993; 33: 902–9</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>902</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>902</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Zempleni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JR</namePart><namePart type="family">Galloway</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DB</namePart><namePart type="family">McCormick</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zempleni J, Galloway JR, McCormick DB: Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am J Clin Nutr 1996; 63: 54–66</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>54</start><end>66</end></extent></part><relatedItem type="host"><titleInfo><title>Am J Clin Nutr</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>63</number></detail><extent unit="pages"><start>54</start><end>66</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Studies on the toxicity and pharmacology of riboflavin</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Unna</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Greslin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Unna K, Greslin J: Studies on the toxicity and pharmacology of riboflavin. J Pharmacol Exp Ther 1942; 75: 75–80</note><part><date>1942</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>75</start><end>80</end></extent></part><relatedItem type="host"><titleInfo><title>J Pharmacol Exp Ther</title></titleInfo><part><date>1942</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><extent unit="pages"><start>75</start><end>80</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>Ultraviolet radiation‐induced photodegradation and 1O2,</title></titleInfo><name type="personal"><namePart type="given">PC</namePart><namePart type="family">Joshi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Joshi PC: Ultraviolet radiation‐induced photodegradation and 1O2, production by riboflavin, lumichrome and lumiflavin. Indian J Biochem Biophys 1989; 26: 186–89</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>186</start><end>89</end></extent></part><relatedItem type="host"><titleInfo><title>Indian J Biochem Biophys</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>186</start><end>89</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>Effects of dietary supplementation with vitamin E, riboflavin and selenium on central nervous system oxygen toxicity</title></titleInfo><name type="personal"><namePart type="given">WY</namePart><namePart type="family">Boadi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Thaire</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Kerem</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Yannai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boadi WY, Thaire L, Kerem D, Yannai S: Effects of dietary supplementation with vitamin E, riboflavin and selenium on central nervous system oxygen toxicity. Pharmacol Toxicol 1991; 68: 77–82</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>77</start><end>82</end></extent></part><relatedItem type="host"><titleInfo><title>Pharmacol Toxicol</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>68</number></detail><extent unit="pages"><start>77</start><end>82</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Assessment of the genotoxic potential of riboflavin and lumiflavin. A. Effect of metabolic enzymes</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kale</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Harikumar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Nair</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Netrawali</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kale H, Harikumar P, Nair PM, Netrawali MS: Assessment of the genotoxic potential of riboflavin and lumiflavin. A. Effect of metabolic enzymes. Mutat Res 1992; 298: 9–16</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>9</start><end>16</end></extent></part><relatedItem type="host"><titleInfo><title>Mutat Res</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>9</start><end>16</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Comparison of the DNA‐damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical</title></titleInfo><name type="personal"><namePart type="given">PC</namePart><namePart type="family">Joshi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Joshi PC: Comparison of the DNA‐damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical . Mech Toxicol Lett 1985; 26: 211–17</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>211</start><end>17</end></extent></part><relatedItem type="host"><titleInfo><title>Mech Toxicol Lett</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>211</start><end>17</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Photosensitized formation of 8‐hydroxydeoxyguanosine in cellular DNA by riboflavin</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Yamamoto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Nishimura</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kasai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Yamamoto F, Nishimura S, Kasai H: Photosensitized formation of 8‐hydroxydeoxyguanosine in cellular DNA by riboflavin. Biochem Biophys Res Commun 1992; 187: 809–13</note><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>809</start><end>13</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem Biophys Res Commun</title></titleInfo><part><date>1992</date><detail type="volume"><caption>vol.</caption><number>187</number></detail><extent unit="pages"><start>809</start><end>13</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>Photobinding and photoreactivity of riboflavin in the presence of macromolecules</title></titleInfo><name type="personal"><namePart type="given">HB</namePart><namePart type="family">Kostenbauder</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PP</namePart><namePart type="family">DeLuca</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CR</namePart><namePart type="family">Kowarski</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kostenbauder HB, DeLuca PP, Kowarski CR: Photobinding and photoreactivity of riboflavin in the presence of macromolecules. J Pharm Sci 1965; 54: 1243–51</note><part><date>1965</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1243</start><end>51</end></extent></part><relatedItem type="host"><titleInfo><title>J Pharm Sci</title></titleInfo><part><date>1965</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>1243</start><end>51</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>DNA strand breaks in mammalian cells exposed to light in the presence of riboflavin and tryptophan</title></titleInfo><name type="personal"><namePart type="given">ME</namePart><namePart type="family">Hoffmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Meneghini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hoffmann ME, Meneghini R: DNA strand breaks in mammalian cells exposed to light in the presence of riboflavin and tryptophan. Photochem Photobiol 1979; 29: 299–303</note><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>299</start><end>303</end></extent></part><relatedItem type="host"><titleInfo><title>Photochem Photobiol</title></titleInfo><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>29</number></detail><extent unit="pages"><start>299</start><end>303</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>Further observations on the photooxidation of DNA in the presence of riboflavin</title></titleInfo><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Speck</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HS</namePart><namePart type="family">Rosenkranz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Rosenkranz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Speck WT, Rosenkranz HS, Rosenkranz S: Further observations on the photooxidation of DNA in the presence of riboflavin. Biochim Biophys Acta 1976; 435: 39–44</note><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>435</number></detail><extent unit="pages"><start>39</start><end>44</end></extent></part><relatedItem type="host"><titleInfo><title>Biochim Biophys Acta</title></titleInfo><part><date>1976</date><detail type="volume"><caption>vol.</caption><number>435</number></detail><extent unit="pages"><start>39</start><end>44</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Photosensitized inactivation of ribonucleic acids in the presence of riboflavin</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tsugita</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Okada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Uehara</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tsugita A, Okada Y, Uehara K: Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta 1965; 103: 360–363</note><part><date>1965</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>360</start><end>363</end></extent></part><relatedItem type="host"><titleInfo><title>Biochim Biophys Acta</title></titleInfo><part><date>1965</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>360</start><end>363</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Modulation of carcinogen‐induced DNA damage and repair enzyme activity by dietary riboflavin</title></titleInfo><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Webster</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MD</namePart><namePart type="family">Gawde</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RK</namePart><namePart type="family">Bhattacharya</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Webster RP, Gawde MD, Bhattacharya RK: Modulation of carcinogen‐induced DNA damage and repair enzyme activity by dietary riboflavin. Cancer Lett 1996; 98: 129–35</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>129</start><end>35</end></extent></part><relatedItem type="host"><titleInfo><title>Cancer Lett</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>129</start><end>35</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Riboflavin photoinactivation procedure inactivates significant levels of bacteria and produces a culture negative product</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Douglas</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Urioste</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodrich L, Douglas I, Urioste M: Riboflavin photoinactivation procedure inactivates significant levels of bacteria and produces a culture negative product. Transfusion 2002; 42: 16S</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>16S</start></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>16S</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Riboflavin and UV light inactivate enveloped and non‐enveloped viruses in platelet concentrates under conditions which maintain cell quality</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Ghielli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Hansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Woolum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gampp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Keil</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodrich L, Ghielli M, Hansen E, Woolum M, Gampp D, Goodrich R, Keil S: Riboflavin and UV light inactivate enveloped and non‐enveloped viruses in platelet concentrates under conditions which maintain cell quality. Vox Sang 2002; 83: 111</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>111</start></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>111</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Effective viral and bacterial kill with good cell quality achieved with riboflavin and UV light</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Hansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gampp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Woolum</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Keil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Selassie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Estrada</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Urioste</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Douglas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>The 9th Congress of the World Apheresis Association Abstract Book</title></titleInfo><originInfo><publisher>Paris, France</publisher></originInfo><part><date>2002</date><extent unit="pages"><start>16</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Inactivation of viruses in blood products (platelets, plasma and red cells)</title></titleInfo><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodrich RP: Inactivation of viruses in blood products (platelets, plasma and red cells). Transfus Clin Biol 2001; 8: 103S</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>103S</start></extent></part><relatedItem type="host"><titleInfo><title>Transfus Clin Biol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>103S</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Mirosol pathogen reduction technology: riboflavin‐based plasma process inactivates intracellular and extracellular human immunodeficiency virus</title></titleInfo><name type="personal"><namePart type="given">V</namePart><namePart type="family">Kumar</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Motheral</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Luzniak</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Goodrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kumar V, Motheral T, Luzniak G, Goodrich RP: Mirosol pathogen reduction technology: riboflavin‐based plasma process inactivates intracellular and extracellular human immunodeficiency virus. J Clin Apheresis 2003; 18: 84</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>84</start></extent></part><relatedItem type="host"><titleInfo><title>J Clin Apheresis</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>18</number></detail><extent unit="pages"><start>84</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light</title></titleInfo><name type="personal"><namePart type="given">PH</namePart><namePart type="family">Ruane</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Edrich</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Gampp</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SD</namePart><namePart type="family">Keil</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Leonard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RP</namePart><namePart type="family">Goodriche</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodriche RP: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877–85</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>877</start><end>85</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>877</start><end>85</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>In vitro evaluation of platelet concentrates, prepared from pooled buffy coats, stored for 8 days after filtration</title></titleInfo><name type="personal"><namePart type="given">MN</namePart><namePart type="family">Boomgaard</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Joustra‐Dijkhuis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CW</namePart><namePart type="family">Gouwerok</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">I</namePart><namePart type="family">Steneker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Reesink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Loos</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RN</namePart><namePart type="family">Pietersz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">De Korte</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Boomgaard MN, Joustra‐Dijkhuis AM, Gouwerok CW, Steneker I, Reesink HW, Loos JA, Pietersz RN, De Korte D: In vitro evaluation of platelet concentrates, prepared from pooled buffy coats, stored for 8 days after filtration. Transfusion 1994; 34: 311–6</note><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>311</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1994</date><detail type="volume"><caption>vol.</caption><number>34</number></detail><extent unit="pages"><start>311</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation</title></titleInfo><name type="personal"><namePart type="given">RN</namePart><namePart type="family">Pietersz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">De Korte</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HW</namePart><namePart type="family">Reesink</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WJ</namePart><namePart type="family">Dekker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Van Den Ende</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Loos</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pietersz RN, De Korte D, Reesink HW, Dekker WJ, Van Den Ende A, Loos JA: Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989; 56: 145–50</note><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>145</start><end>50</end></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>145</start><end>50</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Automation in blood component preparation</title></titleInfo><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Loos</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book-chapter</genre><relatedItem type="host"><titleInfo><title>Transfusion Medicine: Recent Technological Advances</title></titleInfo><originInfo><publisher>A.R. Liss</publisher></originInfo><part><date>1986</date><extent unit="pages"><start>333</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit27"><titleInfo><title>Quantitative assessment of platelet morphology by light scattering: a potential method for the evaluation of platelets for transfusion</title></titleInfo><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Fratantoni</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Poindexter</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RF</namePart><namePart type="family">Bonner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fratantoni JC, Poindexter BJ, Bonner RF: Quantitative assessment of platelet morphology by light scattering: a potential method for the evaluation of platelets for transfusion. J Lab Clin Med 1984; 103: 620–31</note><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>620</start><end>31</end></extent></part><relatedItem type="host"><titleInfo><title>J Lab Clin Med</title></titleInfo><part><date>1984</date><detail type="volume"><caption>vol.</caption><number>103</number></detail><extent unit="pages"><start>620</start><end>31</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit28"><titleInfo><title>A study of variables affecting the quality of platelets stored at ‘room temperature’</title></titleInfo><name type="personal"><namePart type="given">TJ</namePart><namePart type="family">Kunicki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Tuccelli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Becker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RH</namePart><namePart type="family">Aster</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kunicki TJ, Tuccelli M, Becker GA, Aster RH: A study of variables affecting the quality of platelets stored at ‘room temperature’. Transfusion 1975; 15: 414–21</note><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>414</start><end>21</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>414</start><end>21</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit29"><titleInfo><title>A multi‐laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Holme</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Moroff</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holme S, Moroff G, Murphy S: A multi‐laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998; 38: 31–40</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>31</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>31</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit30"><titleInfo><title>Platelet surface P‐selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT)</title></titleInfo><name type="personal"><namePart type="given">LJ</namePart><namePart type="family">Dumont</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">VandenBroeke</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KA</namePart><namePart type="family">Ault</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dumont LJ, VandenBroeke T, Ault KA: Platelet surface P‐selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfus Med Rev 1999; 13: 31–42</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>31</start><end>42</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med Rev</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>31</start><end>42</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit31"><titleInfo><title>Vesiculation of platelets during in vitro aging</title></titleInfo><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Bode</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Orton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MJ</namePart><namePart type="family">Frye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Udis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bode AP, Orton SM, Frye MJ, Udis BJ: Vesiculation of platelets during in vitro aging. Blood 1991; 77: 887–95</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>887</start><end>95</end></extent></part><relatedItem type="host"><titleInfo><title>Blood</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>77</number></detail><extent unit="pages"><start>887</start><end>95</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit32"><titleInfo><title>Growth of bacteria in platelet concentrates obtained from whole blood stored for 16 hours at 22 degrees C before component preparation</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Sanz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Pereira</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Vila</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AI</namePart><namePart type="family">Faundez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Gomez</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ordinas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sanz C, Pereira A, Vila J, Faundez AI, Gomez J, Ordinas A: Growth of bacteria in platelet concentrates obtained from whole blood stored for 16 hours at 22 degrees C before component preparation. Transfusion 1997; 37: 251–4</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>251</start><end>4</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>37</number></detail><extent unit="pages"><start>251</start><end>4</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit33"><titleInfo><title>The quality of platelets after storage for 7 days</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Cardigan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Williamson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cardigan R, Williamson LM: The quality of platelets after storage for 7 days. Transfus Med 2003; 13: 173–87</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>173</start><end>87</end></extent></part><relatedItem type="host"><titleInfo><title>Transfus Med</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>173</start><end>87</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit34"><titleInfo><title>Gorlin JB, ed.: Standards for Blood Banks and Transfusion Services, edn 21. Bethesda, Maryland, USA, American Association of Blood Banks, 2002</title></titleInfo><note type="citation/reference">Gorlin JB, ed.: Standards for Blood Banks and Transfusion Services, edn 21. Bethesda, Maryland, USA, American Association of Blood Banks, 2002</note><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Gorlin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>book</genre><originInfo><publisher>American Association of Blood Banks</publisher></originInfo><part><date>2002</date></part></relatedItem><relatedItem type="references" displayLabel="cit35"><titleInfo><title>Council of Europe:Guide to the Preparation, Use and Quality Assurance of Blood Components, edn 10. Strasbourg, France, Council of Europe Publishing, 2004</title></titleInfo><name type="corporate"><namePart>Council of Europe:</namePart></name><note type="citation/reference">Council of Europe: Guide to the Preparation, Use and Quality Assurance of Blood Components, edn 10. Strasbourg, France, Council of Europe Publishing, 2004</note><genre>book</genre><originInfo><publisher>Council of Europe Publishing</publisher></originInfo><part><date>2004</date></part></relatedItem><relatedItem type="references" displayLabel="cit36"><titleInfo><title>Platelet activation may explain the storage lesion in platelet concentrates</title></titleInfo><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Bode</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bode AP: Platelet activation may explain the storage lesion in platelet concentrates. Blood Cells 1990; 16: 109–25</note><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>109</start><end>25</end></extent></part><relatedItem type="host"><titleInfo><title>Blood Cells</title></titleInfo><part><date>1990</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><extent unit="pages"><start>109</start><end>25</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit37"><titleInfo><title>Apoptotic activity in stored human platelets</title></titleInfo><name type="personal"><namePart type="given">PL</namePart><namePart type="family">Perrotta</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CL</namePart><namePart type="family">Perrotta</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EL</namePart><namePart type="family">Snyder</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Perrotta PL, Perrotta CL, Snyder EL: Apoptotic activity in stored human platelets. Transfusion 2003; 43: 526–35</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>526</start><end>35</end></extent></part><relatedItem type="host"><titleInfo><title>Transfusion</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>526</start><end>35</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit38"><titleInfo><title>Assessment of the acute toxicity and genotoxicity risks associated with lumichrome, the primary photoproduct of riboflavin</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Piper</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Murphy</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Schuyler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Piper J, Murphy S, Schuyler R et al.: Assessment of the acute toxicity and genotoxicity risks associated with lumichrome, the primary photoproduct of riboflavin. Vox Sang 2002; 83: 192</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>192</start></extent></part><relatedItem type="host"><titleInfo><title>Vox Sang</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>83</number></detail><extent unit="pages"><start>192</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit39"><titleInfo><title>Evaluation of genotoxicity and acute toxicity risks associated with a riboflavin based pathogen inactivation process</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Piper</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Hansen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Woolum</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Piper J, Hansen E, Woolum M et al.: Evaluation of genotoxicity and acute toxicity risks associated with a riboflavin based pathogen inactivation process. Int J Toxicol 2001; 20: 404</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>404</start></extent></part><relatedItem type="host"><titleInfo><title>Int J Toxicol</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>20</number></detail><extent unit="pages"><start>404</start></extent></part></relatedItem></relatedItem><identifier type="istex">933E5413A4419F06FFEB2ECA3F8E362037753B24</identifier><identifier type="ark">ark:/67375/WNG-7MMLP8DQ-P</identifier><identifier type="DOI">10.1111/j.1423-0410.2004.00548.x</identifier><identifier type="ArticleID">VOX548</identifier><accessCondition type="use and reproduction" contentType="copyright">© Wiley. All rights reserved.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-16</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-7MMLP8DQ-P/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001C87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:933E5413A4419F06FFEB2ECA3F8E362037753B24
|texte= Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen‐reduction technology‐treated apheresis platelet products
}}
| This area was generated with Dilib version V0.6.33. |  |